Breaking News Instant updates and real-time market news.

ANAB

AnaptysBio

$71.18

5.26 (7.98%)

, REGN

Regeneron

$415.32

3.22 (0.78%)

11:50
03/12/19
03/12
11:50
03/12/19
11:50

AnaptysBio jumps after JPMorgan surveys doctors on asthma data

Shares of AnaptysBio (ANAB) are higher after JPMorgan analyst Anupam Rama asked 60 U.S. physicians about the company's Phase 2a eosinophilic asthma data for etokimab. While acknowledging the data for etokimab are early stage, Rama told investors earlier in a research note that he is "broadly encouraged" by the enthusiasm of the surveyed physicians. Regeneron's (REGN) cautious commentary on monotherapy activity of its IL-33 antibody, REGN3500, has emerged as an overhang on AnaptysBio's etokimab asthma program, but anecdotal feedback in the survey suggests IL-33 inhibition is viewed as an "interesting mechanism," Rama wrote. He sees a "number of potential value creating catalysts" for AnaptysBio shares in mid-2019, including Phase 2b data of etokimab in atopic dermatitis, Phase 2 data of etokimab in chronic rhinosinusitis with nasal polyps, and Phase 2 data from ANB019 in generalized pustular psoriasis. The analyst keeps an Overweight rating on AnaptysBio. The stock in late morning trading is up 9%, or $6.05, to $71.99 in late morning trading.

ANAB

AnaptysBio

$71.18

5.26 (7.98%)

REGN

Regeneron

$415.32

3.22 (0.78%)

  • 28

    Apr

  • 13

    May

ANAB AnaptysBio
$71.18

5.26 (7.98%)

11/21/18
11/21/18
INITIATION
Target $115

Overweight
JPMorgan sees attractive entry point, starts AnaptysBio at Overweight
As previously reported, JPMorgan analyst Anupam Rama started AnaptysBio with an Overweight rating and $115 price target, stating that he sees an attractive entry point with the stock down over 35% since early October. The company's proprietary antibody development approach has been validated by both data and partnerships, while its lead asset etokimab has delivered positive early-stage data in both atopic dermatitis and eosinophilic asthma, Rama tells investors.
12/20/18
HCWC
12/20/18
INITIATION
Target $126
HCWC
Buy
AnaptysBio initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein started AnaptysBio with a Buy rating and $126 price target. While the company "emerges as a newcomer in the competitive field of inflammatory diseases," it may differentiate itself with a "double play of two wholly owned assets (novel targets) and a proprietary antibody platform," Fein tells investors in a research note. AnaptysBio is "studded with" two clinical stage biologics, five ongoing clinical programs, two licensing partners, and an array of data readouts in the next 12-18 months, says the analyst.
01/18/19
RHCO
01/18/19
NO CHANGE
Target $125
RHCO
Buy
AnaptysBio price target lowered to $125 from $156 at SunTrust
SunTrust analyst Joon Lee lowered his price target on AnaptysBio to $125, citing increasing competition for its product. The analyst keeps his Buy rating however and expects its stock to show "significant upside from current levels in 2019" ahead of the four major data readouts to follow "already promising" phase 2 proof of concept data in atopic dermatitis and asthma. Lee is overall positive on AnaptysBio's "proprietary antibody generation platform that is able to mimic natural in vivo process of antibody diversity generation in an in vitro system".
02/22/19
GUGG
02/22/19
INITIATION
Target $135
GUGG
Buy
AnaptysBio initiated with a Buy at Guggenheim
Guggenheim analyst Yatin Suneja initiated AnaptysBio with a Buy rating and $135 price target, calling its lead asset, etokimab, a "a pipeline-in-a-product with blockbuster potential" given its potential for broad applicability across multiple atopic diseases.
REGN Regeneron
$415.32

3.22 (0.78%)

02/25/19
PIPR
02/25/19
NO CHANGE
Target $475
PIPR
Overweight
Verdict upholding Amgen patent should not impact Regeneron, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $475 price target on Regeneron (REGN), saying that today's verdict upholding the validity of two Amgen (AMGN) patents should not matter much because U.S. Praluent represents just $12 per share in its valuation. The analyst adds that Regeneron still has "several procedural steps to execute in the coming months aiming to change the verdict or request another new trial", and that today's decision marks the second time that a jury ruled in Amgen's favor.
02/26/19
PIPR
02/26/19
NO CHANGE
Target $487
PIPR
Overweight
Regeneron price target raised to $487 from $475 at Piper Jaffray
Piper Jaffray analyst Christopher Raymond raised his price target for Regeneron Pharmaceuticals to $487 after adjusting his Dupixent model to include impact of label expansion into adolescent atopic dermatitis and chronic rhinosinusitis with nasal polyps. Dupixent's clinical profile "continues to impress" in showing meaningful, statistically significant improvements across a host of measures including sinus opacification and systemic corticosteroid use, Raymond tells investors in a research note. The analyst keeps an Overweight rating on Regeneron.
02/26/19
MSCO
02/26/19
NO CHANGE
Target $215
MSCO
Overweight
Morgan Stanley says Sanofi, Regeneron face 'uphill battle' in Amgen patent fight
After a Delaware district court ruled in favor of Amgen (AMGN) upholding the validity of patents on PCSK9 antibodies in litigation versus Sanofi (SNY) and Regeneron (REGN), Morgan Stanley analyst Matthew Harrison said he believes Sanofi and Regeneron face an "uphill battle" given this was the second district court trial to find in favor of Amgen. Harrison, who said he expects "no acute impact" to Amgen or Regeneron shares given the limited recent investor focus on PCSK9 uptake, keeps an Overweight rating on Amgen shares.
02/26/19
JEFF
02/26/19
NO CHANGE
JEFF
The Medicines Co. may have only PCSK9 not infringing Amgen, says Jefferies
Following yesterday's patent win over Sanofi (SNY) and Regeneron (REGN), Amgen (AMGN) now possesses broad patents which will be difficult for most competitors to circumvent, Jefferies analyst Biren Amin tells investors in a research note. The Medicines Co.'s (MDCO) inclisiran, which falls outside of the claims as a purely RNA-directed agent, could be the only PCSK9 mechanism which does not infringe Amgen's Repatha, Amin contends. He believes that should Sanofi and Regeneron's Praluent be hit with a permanent injunction, inclisiran is "well positioned to carve out market share in a growing PCSK9 class."

TODAY'S FREE FLY STORIES

PYPL

PayPal

$118.65

-1.22 (-1.02%)

, V

Visa

$179.18

-1.34 (-0.74%)

08:31
07/20/19
07/20
08:31
07/20/19
08:31
Periodicals
MasterCard, Visa among best stocks to play fintech boom, Barron's says »

The fintech units within…

PYPL

PayPal

$118.65

-1.22 (-1.02%)

V

Visa

$179.18

-1.34 (-0.74%)

MA

MasterCard

$275.51

-1.11 (-0.40%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 24

    Jul

  • 30

    Jul

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

, SBNY

Signature Bank

$123.87

1.07 (0.87%)

08:28
07/20/19
07/20
08:28
07/20/19
08:28
Periodicals
KeyCorp, U.S. Bancorp better positioned for Fed rate cut, Barron's says »

KeyCorp (KEY), Signature…

USB

U.S. Bancorp

$54.98

-0.2 (-0.36%)

SBNY

Signature Bank

$123.87

1.07 (0.87%)

KEY

KeyCorp

$17.45

0.15 (0.87%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 29

    Aug

  • 16

    Oct

CMG

Chipotle

$746.80

-17.43 (-2.28%)

08:24
07/20/19
07/20
08:24
07/20/19
08:24
Periodicals
Chipotle stock made 'stunning' comeback, Barron's says »

Chipotle's stock is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Sep

BYND

Beyond Meat

$176.65

6.28 (3.69%)

07:40
07/20/19
07/20
07:40
07/20/19
07:40
Periodicals
Beyond Meat could spike after earnings, Barron's says »

After rising so…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jul

NFLX

Netflix

$315.10

-10.04 (-3.09%)

07:37
07/20/19
07/20
07:37
07/20/19
07:37
Periodicals
Netflix's problems have only just begun, Barron's says »

Netflix has a problem and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, TGT

Target

$88.02

-0.48 (-0.54%)

07:34
07/20/19
07/20
07:34
07/20/19
07:34
Periodicals
Time to aim higher on Target's stock, Barron's says »

As retailers have…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

TGT

Target

$88.02

-0.48 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 21

    Aug

  • 19

    Sep

  • 25

    Sep

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, FDX

FedEx

$167.08

1.69 (1.02%)

07:31
07/20/19
07/20
07:31
07/20/19
07:31
Periodicals
FedEx ups game amid e-commerce growth, Barron's says »

It is time to embrace…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

FDX

FedEx

$167.08

1.69 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 30

    Jul

  • 31

    Jul

  • 17

    Sep

  • 13

    Nov

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

, MSFT

Microsoft

$136.62

0.33 (0.24%)

07:27
07/20/19
07/20
07:27
07/20/19
07:27
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

MSFT

Microsoft

$136.62

0.33 (0.24%)

ORCL

Oracle

$57.55

-0.58 (-1.00%)

AZN

AstraZeneca

$40.11

-0.61 (-1.50%)

BMY

Bristol-Myers

$43.32

-0.72 (-1.63%)

LLY

Eli Lilly

$106.75

-1.57 (-1.45%)

GSK

GlaxoSmithKline

$40.97

-0.44 (-1.06%)

JNJ

Johnson & Johnson

$130.41

-1.62 (-1.23%)

MRK

Merck

$81.39

-1.28 (-1.55%)

NVS

Novartis

$93.58

-0.715 (-0.76%)

PFE

Pfizer

$42.78

-0.28 (-0.65%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$41.94

-0.01 (-0.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 24

    Jul

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 29

    Jul

  • 30

    Jul

  • 30

    Jul

  • 30

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 18

    Aug

  • 19

    Aug

  • 26

    Aug

  • 27

    Aug

  • 28

    Aug

  • 02

    Sep

  • 09

    Sep

  • 16

    Sep

  • 16

    Sep

  • 20

    Sep

  • 23

    Sep

  • 25

    Sep

  • 02

    Oct

  • 15

    Oct

  • 04

    Nov

BHVN

Biohaven Pharmaceutical

$44.16

-0.61 (-1.36%)

18:12
07/19/19
07/19
18:12
07/19/19
18:12
Hot Stocks
Biohaven receives CRL from FDA for application seeking NURTEC approval »

Biohaven Pharmaceutical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

CE

Celanese

$107.01

0.9 (0.85%)

18:01
07/19/19
07/19
18:01
07/19/19
18:01
Hot Stocks
Celanese announces acetyl intermediates price increases »

Celanese Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

F

Ford

$10.20

-0.06 (-0.58%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Periodicals
Ford plans to lay off 185 employees at Ontario plant, Reuters reports »

A union local said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 23

    Oct

RTN

Raytheon

$178.55

2.45 (1.39%)

17:48
07/19/19
07/19
17:48
07/19/19
17:48
Hot Stocks
Raytheon awarded $191.01M Air Force contract modification »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

UTX

United Technologies

$132.37

1.08 (0.82%)

17:44
07/19/19
07/19
17:44
07/19/19
17:44
Hot Stocks
United Technologies awarded $253.71M Air Force contract »

United Technologies has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

LMT

Lockheed Martin

$356.90

0.675 (0.19%)

17:40
07/19/19
07/19
17:40
07/19/19
17:40
Hot Stocks
Lockheed Martin awarded $1.47B Missile Defense Agency contract modification »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

ARES

Ares Management

$28.13

-0.305 (-1.07%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Syndicate
Breaking Syndicate news story on Ares Management »

Ares Management files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 06

    Aug

HAFC

Hanmi Financial

$21.68

-0.105 (-0.48%)

17:33
07/19/19
07/19
17:33
07/19/19
17:33
Hot Stocks
Hanmi Financial to delay release of Q2 results »

Hanmi Financial announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

PAYS

Paysign

$17.49

-0.48 (-2.67%)

17:32
07/19/19
07/19
17:32
07/19/19
17:32
Syndicate
Breaking Syndicate news story on Paysign »

Paysign files $150M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEOH

Methanex

$43.19

0.83 (1.96%)

17:28
07/19/19
07/19
17:28
07/19/19
17:28
Hot Stocks
Methanex reaches final investment decision on methanol plant in Geismar, LA »

Methanex Corporation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

17:17
07/19/19
07/19
17:17
07/19/19
17:17
Conference/Events
Credit Suisse biotech analysts to hold an analyst/industry conference call »

Biotech Analysts provide…

17:14
07/19/19
07/19
17:14
07/19/19
17:14
Conference/Events
UBS retail/hardlines analyst to hold an analyst/industry conference call »

Retail/Hardlines Analyst…

SHIP

Seanergy Marine

$0.64

-0.0425 (-6.25%)

17:05
07/19/19
07/19
17:05
07/19/19
17:05
Hot Stocks
Seanergy Maritime receives noncompliance notice from Nasdaq »

Seanergy Maritime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SONM

Sonim

$13.42

0.24 (1.82%)

16:41
07/19/19
07/19
16:41
07/19/19
16:41
Conference/Events
Sonim management to meet with Oppenheimer »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 26

    Jul

  • 12

    Sep

KINS

Kingstone Companies

$8.81

0.09 (1.03%)

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Hot Stocks
Kingstone names Barry Goldstein CEO »

Kingstone Companies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 09

    Aug

16:30
07/19/19
07/19
16:30
07/19/19
16:30
Options
Preliminary option volume of 22.6M today »

Preliminary option volume…

BA

Boeing

$377.34

16.17 (4.48%)

, MSFT

Microsoft

$136.62

0.33 (0.24%)

16:24
07/19/19
07/19
16:24
07/19/19
16:24
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks were tentatively…

BA

Boeing

$377.34

16.17 (4.48%)

MSFT

Microsoft

$136.62

0.33 (0.24%)

AMZN

Amazon.com

$1,964.78

-13.57 (-0.69%)

AAPL

Apple

$202.62

-3.02 (-1.47%)

WMT

Walmart

$113.91

-0.77 (-0.67%)

DIS

Disney

$139.86

-1.76 (-1.24%)

GCI

Gannett

$9.43

1.53 (19.37%)

CRWD

Crowdstrike

$83.50

10.75 (14.78%)

SKX

Skechers

$39.00

4.25 (12.23%)

PACB

Pacific Biosciences

$5.34

-0.53 (-9.03%)

ILMN

Illumina

$293.10

-5.44 (-1.82%)

CHWY

Chewy

$30.70

-2.09 (-6.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 25

    Jul

  • 29

    Jul

  • 30

    Jul

  • 03

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 15

    Aug

  • 03

    Sep

  • 25

    Sep

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.